TrianglePUBLICATIONS · 30547695
A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Leuk Lymphoma
- Publication date
- 2019 Apr
- First author
- Hapgood G
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Hapgood G
- type
- Author
- name
- Stone JM
- type
- Author
- name
- Zannino D
- type
- Author
- name
- George A
- type
- Author
- name
- Marlton P
- type
- Author
- name
- Prince HM
- type
- Author
- name
- Hui CH
- type
- Author
- name
- Prosser I
- type
- Author
- name
- Lewis ID
- type
- Author
- name
- Bradstock K
- type
- Author
- name
- Seymour JF
- type
- Author
- name
- Australasian Leukaemia and Lymphoma Group
- type
- CollectiveName
Complete bibliographic record and source provenance
- authors
- name
- Hapgood G
- type
- Author
- name
- Stone JM
- type
- Author
- name
- Zannino D
- type
- Author
- name
- George A
- type
- Author
- name
- Marlton P
- type
- Author
- name
- Prince HM
- type
- Author
- name
- Hui CH
- type
- Author
- name
- Prosser I
- type
- Author
- name
- Lewis ID
- type
- Author
- name
- Bradstock K
- type
- Author
- name
- Seymour JF
- type
- Author
- name
- Australasian Leukaemia and Lymphoma Group
- type
- CollectiveName
- bibliography ids
- nci-bib-091e1f1aca120a82e2ce3049
- book metadata
- content sha256
- 183f45559aaf7e045759ccc0a7526c2d2a5aedc4db072dae0844904de8eb96f4
- document type
- citation
- dois
- 10.1080/10428194.2018.1516873
- electronic publication date
- display
- 2018 Dec 14
- precision
- day
- year
- 2018
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:30547695
- immutable id
- pubmed:30547695@183f45559aaf7e045759ccc0a7526c2d2a5aedc4db072dae0844904de8eb96f4
- journal
- abbreviation
- Leuk Lymphoma
- issn electronic
- 1029-2403
- issn print
- 1026-8022
- issue
- 4
- name
- Leukemia & lymphoma
- nlm unique id
- 9007422
- pages
- 904-911
- volume
- 60
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 30547695
- provenance
- batch id
- 438b2803888025c6cf56
- provider
- NCBI PubMed ESummary
- record sha256
- a32ed6ecd3039c1438e4c357689e839572348c4ad8ff5cf7f5370a61f3620c40
- response sha256
- 0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
- retrieved at
- 2026-09-09T23:47:36.359220+00:00
- publication date
- display
- 2019 Apr
- precision
- month
- year
- 2019
- publication types
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.
Preserved source evidence · Independent clinical review pending · Not medical advice